Related Experiment Video

Updated: May 24, 2026

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

Histologic remission of cardiac amyloidosis: a case report

Matthew R Nelson1, Louis A Lanza, Craig B Reeder

  • 1Division of Cardiovascular Diseases, Mayo Clinic Scottsdale, Arizona, USA.

Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis
|March 8, 2012
PubMed

Insights

Cardiac amyloidosis survival depends on heart involvement. Echocardiographic wall thinning after treatment suggests complete reversal of amyloid deposits is possible with timely intervention.

Area of Science:

  • Cardiology
  • Oncology
  • Pathology

Background:

  • Cardiac involvement is the primary determinant of survival in amyloid light chain amyloidosis.
  • Echocardiographic assessment of cardiac wall thickness changes shows potential as a survival predictor.
  • Previous observations noted wall thickness regression and heart failure resolution in some hematologic responders.

Observation:

  • This study presents a case of immunoglobulin light chain cardiac amyloidosis.
  • The patient received treatment, leading to echocardiographic evidence of cardiac wall thinning.
  • Cardiac biopsies confirmed complete histologic remission of amyloid deposits.

Findings:

  • Treatment resulted in significant echocardiographic wall thinning.
  • Histologic examination of cardiac biopsies revealed complete resolution of amyloid fibrils.
  • This indicates a potential mechanism for treatment response in cardiac amyloidosis.

Implications:

  • Complete reversal of cardiac amyloid deposition may be achievable with appropriately timed treatment.
  • This finding opens new avenues for managing cardiac amyloidosis and improving patient outcomes.
  • Further research into the reversibility of amyloidosis is warranted.

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...